An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Therefore, originator products do not experience a meaningful deterioration ... we announced earlier this year that we regained all us and rusted rights from AstraZeneca with the exception of South ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

The personal luxury goods market looks set to face its first slowdown since the Global Financial Crisis, excluding the Covid ...

Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing the ...

Although some products like Imfinzi/Imjudo and Soliris underperformed, overall, the company’s performance was bolstered by significant gains in other segments, such as Symbicort and Ultomiris.

But Soriot called his tariff policy "irrelevant" to AstraZeneca because the company does not source products from China for ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

AstraZeneca is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The United Kingdom-based global biopharmaceutical company said it ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...